Rocaltrol (calcitriol)

Rocaltrol is a well-established brand of calcitriol, a synthetic vitamin D analog used to regulate calcium levels in the body, primarily for patients with osteoporosis or renal issues. The brand was originally developed and patented by the Swiss pharmaceutical giant F. Hoffmann-La Roche Ltd (Roche) in the late 1970s.

Over the years, the ownership and distribution rights have shifted significantly. In 2020, Triton Partners (through its portfolio company Atnahs, now known as Pharmanovia) acquired the global commercial rights for Rocaltrol from Roche, excluding the markets in China and Japan. In the United States, rights are often managed by specialized pharmaceutical entities like Validus Pharmaceuticals or Searchlight Pharma in Canada.

Manufacturing of Rocaltrol occurs in various locations depending on the region. Significant production facilities are located in Germany (such as Catalent Germany Eberbach GmbH) and Switzerland. Because it is a global brand with complex licensing, the final product found on pharmacy shelves can originate from several different high-standard pharmaceutical manufacturing sites worldwide.